Tumor biomarkers, including CEA, SCC, Cyfra 21 − 1, and NSE, serve as crucial indicators in predicting treatment response in lung cancer patients undergoing ICI therapy [28–30]. The gene discussed is CEACAM5; the disease is lung carcinoma.